Literature DB >> 10645232

Interobserver variation in the histopathological scoring of Helicobacter pylori related gastritis.

X Y Chen1, R W van der Hulst, M J Bruno, A van der Ende, S D Xiao, G N Tytgat, F J Ten Kate.   

Abstract

AIM: To test the reproducibility between two histopathologists of features of Helicobacter pylori gastritis, using the updated Sydney classification.
METHODS: 290 dyspeptic Dutch patients with biopsy proven H pylori infection were enrolled in the study. Gastric antral mucosal biopsy specimens were analysed before and after H pylori eradication treatment. The biopsies were scored semi-quantitatively by two histopathologists, according to the updated Sydney classification system. Variables analysed included the density of H pylori infection, the degree of chronic inflammation, inflammatory activity, atrophy, intestinal metaplasia, and surface epithelial damage. Before grading biopsy specimens, both pathologists reached a consensus on the scoring of gastritis through interactive sessions using a multiheaded microscope. Subsequently all biopsy specimens were graded. Interobserver variability was also analysed using weighted kappa scores.
RESULTS: For interobserver agreement on scoring the various gastritis features a high degree of reproducibility was reached overall. Agreement on grading of atrophy was the lowest; however, moderate to good reproducibility was achieved, with weighted kappa values of 0.49 in the pretreatment biopsies and 0.52 in the post-treatment biopsies. Disagreement was most common in biopsy specimens with lesser degrees of atrophy. A high degree of agreement was obtained for intestinal metaplasia, with weighted kappa values of 0.72 in the pretreatment biopsies and 0.73 in the post-treatment biopsies. The best agreement was reached in the assessment of the density of H pylori both before and after H pylori eradication treatment, with excellent weighted kappa values of 0.76 and 0.95, respectively. The grade of reproducibility of inflammatory activity, superficial epithelial damage, and chronic inflammation was high, with weighted kappa values varying from 0.60 to 0.76 and 0.62 to 0.83 before and after eradication, respectively.
CONCLUSIONS: Reproducibility of grading H pylori related gastritis is high using the updated Sydney system. Despite the novel criteria for scoring atrophy, there was imperfect agreement on this feature between two independent histopathologists.

Entities:  

Mesh:

Year:  1999        PMID: 10645232      PMCID: PMC500953          DOI: 10.1136/jcp.52.8.612

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study.

Authors:  R W van der Hulst; A van der Ende; F W Dekker; F J Ten Kate; J F Weel; J J Keller; S P Kruizinga; J Dankert; G N Tytgat
Journal:  Gastroenterology       Date:  1997-07       Impact factor: 22.682

Review 2.  Recognizing atrophy: another step toward a classification of gastritis.

Authors:  R M Genta
Journal:  Am J Surg Pathol       Date:  1996       Impact factor: 6.394

3.  The Sydney System revisited: the Houston International Gastritis Workshop.

Authors:  R M Genta; M F Dixon
Journal:  Am J Gastroenterol       Date:  1995-07       Impact factor: 10.864

4.  Efforts to improve interobserver agreement in histopathological grading.

Authors:  H C de Vet; J Koudstaal; W S Kwee; D Willebrand; J W Arends
Journal:  J Clin Epidemiol       Date:  1995-07       Impact factor: 6.437

Review 5.  Helicobacter pylori, inflammation, mucosal damage, and apoptosis: pathogenesis and definition of gastric atrophy.

Authors:  R M Genta
Journal:  Gastroenterology       Date:  1997-12       Impact factor: 22.682

Review 6.  Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994.

Authors:  M F Dixon; R M Genta; J H Yardley; P Correa
Journal:  Am J Surg Pathol       Date:  1996-10       Impact factor: 6.394

Review 7.  Helicobacter pylori and gastric carcinogenesis.

Authors:  P Correa
Journal:  Am J Surg Pathol       Date:  1995       Impact factor: 6.394

8.  Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis.

Authors:  H M el-Zimaity; D Y Graham; M T al-Assi; H Malaty; T J Karttunen; D P Graham; R M Huberman; R M Genta
Journal:  Hum Pathol       Date:  1996-01       Impact factor: 3.466

9.  Observer variation in the assessment of chronic gastritis according to the Sydney system.

Authors:  A Andrew; J I Wyatt; M F Dixon
Journal:  Histopathology       Date:  1994-10       Impact factor: 5.087

10.  Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group.

Authors:  E Bayerdörffer; A Neubauer; B Rudolph; C Thiede; N Lehn; S Eidt; M Stolte
Journal:  Lancet       Date:  1995-06-24       Impact factor: 79.321

  10 in total
  15 in total

1.  Histopathology audit of chronic gastritis in India: need for objectivity and training.

Authors:  N Patkar; H Mani; R Moitra; V S Nijhawan; V Srinivas; S D Duhan; S K Nema
Journal:  J Clin Pathol       Date:  2006-05       Impact factor: 3.411

2.  [Source of variation in the diagnosis of Helicobacter pylori-associated multifocal atrophic gastritis.]

Authors:  Luis Eduardo Bravo; Juan Carlos Bravo; José Luis Realpe; Guillermo Zarama; MarÍa Blanca Piazuelo; Pelayo Correa
Journal:  Colomb Med (Cali)       Date:  2008-01

3.  Evaluation of gastric cancer risk using topography of histological gastritis: a large-scaled cross-sectional study.

Authors:  Shinobu Imagawa; Masaharu Yoshihara; Masanori Ito; Shigeto Yoshida; Yoshihiro Wada; Masana Tatsugami; Akemi Takamura; Shinji Tanaka; Ken Haruma; Kazuaki Chayama
Journal:  Dig Dis Sci       Date:  2007-11-13       Impact factor: 3.199

4.  Helicobacter pylori in sleeve gastrectomies: prevalence and rate of complications.

Authors:  Alia Albawardi; Saeeda Almarzooqi; Fawaz Chikh Torab
Journal:  Int J Clin Exp Med       Date:  2013-01-26

5.  Interobserver variation in histopathological assessment of Helicobacter pylori gastritis.

Authors:  Ozlem Aydin; Reyhan Egilmez; Tuba Karabacak; Arzu Kanik
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

6.  Prevalence of Helicobacter pylori infection, chronic gastritis, and intestinal metaplasia in Mozambican dyspeptic patients.

Authors:  Carla Carrilho; Prassad Modcoicar; Lina Cunha; Mamudo Ismail; Acucena Guisseve; Cesaltina Lorenzoni; Fabiola Fernandes; Bárbara Peleteiro; Raquel Almeida; Céu Figueiredo; Leonor David; Nuno Lunet
Journal:  Virchows Arch       Date:  2008-12-20       Impact factor: 4.064

7.  The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology.

Authors:  Marcis Leja; Limas Kupcinskas; Konrads Funka; Agnese Sudraba; Laimas Jonaitis; Audrius Ivanauskas; Dainius Janciauskas; Gediminas Kiudelis; Han-Mo Chiu; Jaw-Town Lin
Journal:  Dig Dis Sci       Date:  2009-11       Impact factor: 3.199

8.  Gastritis staging: interobserver agreement by applying OLGA and OLGIM systems.

Authors:  Sergejs Isajevs; Inta Liepniece-Karele; Dainius Janciauskas; Georgijs Moisejevs; Viesturs Putnins; Konrads Funka; Ilze Kikuste; Aigars Vanags; Ivars Tolmanis; Marcis Leja
Journal:  Virchows Arch       Date:  2014-01-30       Impact factor: 4.064

9.  Epidemiological trends of pre-malignant gastric lesions: a long-term nationwide study in the Netherlands.

Authors:  A C de Vries; G A Meijer; C W N Looman; M K Casparie; B E Hansen; N C T van Grieken; E J Kuipers
Journal:  Gut       Date:  2007-08-14       Impact factor: 23.059

10.  Helicobacter pylori Outer Membrane Protein 18 (Hp1125) Is Involved in Persistent Colonization by Evading Interferon- γ Signaling.

Authors:  Yuqun Shan; Xingxiao Lu; Yingnan Han; Xinpeng Li; Xiao Wang; Chunhong Shao; Lixiang Wang; Zhifang Liu; Wei Tang; Yundong Sun; Jihui Jia
Journal:  Biomed Res Int       Date:  2015-04-06       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.